Table 1.
Survival and prostate cancer incidence in rats receiving L-selenomethionine
| Group | 1 | 2 | 3 |
|---|---|---|---|
| Chemopreventive agent | Control | SeMet | SeMet |
| Chemopreventive agent dose level (mg/kg diet) | - | 1.5 | 3.0 |
| Survival at study termination | 32/39 (82) | 30/39 (77) | 34/40 (85) |
| Effective number of animals for histopathology | 38 | 39 | 37 |
|
No. (%) of rats with lesion: |
|||
| All accessory sex glands combined (dorsolateral and anterior prostate plus seminal vesicle): | |||
| Adenocarcinoma or carcinosarcoma, all | 30 (79) | 30 (77) | 25 (68) |
| Macroscopic size | 11 (29) | 10 (26) | 6 (16) |
| Microscopic size only | 19 (50) | 20 (51) | 19 (51) |
| Carcinoma in situ only | 3 (8) | 5 (13) | 8 (22) |
| Dorsolateral plus anterior prostate (clearly confined to these glands): | |||
| Adenocarcinoma, all | 20 (53) | 17 (44) | 19 (51) |
| Macroscopic size | 0 | 0 | 0 |
| Microscopic size only | 20 (53) | 17 (44) | 19 (51) |
| Carcinoma in situ only | 3 (8) | 4 (10) | 6 (16) |
| Dorsolateral prostate region (originating from dorsolateral or anterior prostate or seminal vesicle): | |||
| Adenocarcinoma or carcinosarcoma, all | 8 (21) | 9 (23) | 6 (16) |
| Macroscopic size | 7 (18) | 7 (18) | 5 (14) |
| Microscopic size only | 1 (3) | 2 (5) | 1 (3) |
| Anterior prostate/seminal vesicle region (originating from anterior prostate or seminal vesicle): | |||
| Adenocarcinoma, all | 5 (13) | 3 (8) | 1 (3) |
| Macroscopic size | 4 (11) | 3 (8) | 1 (3) |
| Microscopic size only | 1 (3) | 0 | 0 |
| Seminal vesicle only (clearly confined to this gland): | |||
| Adenocarcinoma, all | 1 (3) | 4 (10) | 1 (3) |
| Macroscopic size | 0 | 0 | 0 |
| Microscopic size | 1 (3) | 4 (10) | 1 (3) |
| Carcinoma in situ only | 0 | 1 (3) | 2 (5) |
| Sarcoma | 1 (3) | 0 | 0 |